相关实验视频

Updated: Feb 17, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

通过SMAC模仿剂量升级和TGFβ阻断加强质母细胞瘤免疫疗法

Kyle Malone^1,2,3,4, Melanie Dugas^1,2,3, Nathalie Earl^1,2,3,4

¹Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario K1H 8L1, Canada.

Neuro-oncology advances

|February 16, 2026

概括

小分子IAP抗剂 (SMC) 与免疫检查点抑制剂 (ICI) 结合,对质母细胞瘤 (GBM) 治疗有望. 克服中枢神经系统限制的策略是改善GBM患者生存的关键.

科学领域:

神经瘤学神经瘤学
癌症免疫学癌症免疫学
药物开发药物开发

背景情况:

质母细胞瘤 (GBM) 仍然是一个致命的脑癌,生存率的改善很小.
亡抑制剂 (IAP) 蛋白质是GBM的关键生存因素.
小分子IAP对抗剂 (SMAC模仿化合物,SMC) 正在研究用于GBM治疗.

研究的目的:

了解小鼠GBM模型中的SMC限制.
确定加强免疫检查点抑制剂 (ICI) 联合治疗的策略.
为GBM治疗的未来翻译工作提供信息.

主要方法:

使用动物模型,共同培养系统,流细胞计和多重免疫组织化学.
优化了SMC的剂量和输送策略.
研究了对SMC和ICI疗法的耐药性机制.

主要成果:

中枢神经系统 (CNS) 中的GBM细胞位置限制了SMC和ICI治疗的抗GBM免疫力.
增加SMC剂量改善了生存率,减少了巨细胞,增加了微质细胞,并增强了周围免疫力.
由于TGFβ的免疫抑制作用,TGFβ阻塞进一步改善了生存结果.

结论:

在GBM治疗中,SMC可以有效地与ICI相结合.
克服中枢神经系统制定的局限性的策略对于最大限度地提高中枢神经系统疗效至关重要.
优化SMC剂量和结合TGFβ阻断是有前途的治疗途径.

关键词:

在SMAC中,模仿化合物是SMAC的模仿化合物.在TGFβ中,TGFβ是TGFβ.这是一种抗PD-1药物.质母细胞瘤 (glioblastoma) 是一种免疫疗法免疫疗法与瘤相关的巨细胞和微质细胞.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.